Thus, targeting IFIT3 or its downstream effectors may serve as a therapeutic strategy to restore anti-tumor immunity and enhance the efficacy of immune checkpoint inhibitors, making IFIT3 a promising target for cancer immunotherapy. Here, IFIT3 is linked to cancer.